Journal of Medicinal Chemistry
ARTICLE
Laureys, G.; Speleman, F.; Kim, C.; Hou, C.; Hakonarson, H.; Torka-
mani, A.; Schork, N. J.; Brodeur, G. M.; Tonini, G. P.; Rappaport, E.;
Devoto, M.; Maris, J. M. Identification of ALK as a major familial
neuroblastoma predisposition gene. Nature 2008, 455 (7215), 930–936.
(21) Chen, Y.; Takita, J.; Choi, Y. L.; Kato, M.; Ohira, M.; Sanada,
M.; Wang, L.; Soda, M.; Kikuchi, A.; Igarashi, T.; Nakagawara, A.;
Hayashi, Y.; Mano, H.; Ogawa, S. Oncogenic mutations of ALK kinase in
neuroblastoma. Nature 2008, 455 (7215), 971–974.
(22) George, R. E.; Sanda, T.; Hanna, M.; Fr€ohling, S.; Luther, W.;
Zhang, J.; Ahn, Y.; Zhou, W.; London, W. B.; McGrady, P.; Xue, L.;
Zozulya, S.; Gregor, V. E.; Webb, T. R.; Gray, N. S.; Gilliland, D. G.;
Diller, L.; Greulich, H.; Morris, S. W.; Meyerson, M.; Look, A. T.
Activating mutations in ALK provide a therapeutic target in neuroblas-
toma. Nature 2008, 455 (7215), 975–978.
(23) Janoueix-Lerosey, I.; Lequin, D.; Brugiꢁeres, L.; Ribeiro, A.; de
Pontual, L.; Combaret, V.; Raynal, V.; Puisieux, A.; Schleiermacher, G.;
Pierron, G.; Valteau-Couanet, D.; Frebourg, T.; Michon, J.; Lyonnet, S.;
Amiel, J.; Delattre, O. Somatic and germline activating mutations of the
ALK kinase receptor in neuroblastoma. Nature 2008, 455 (7215),
967–970.
(24) Kwak, E. L.; Bang, Y.-J.; Camidge, R.; Shaw, A. T.; Solomon, B.;
Maki, R. G.; Ou, S.-H. I.; Dezube, B. J.; Janne, P. A.; Costa, D. B.; Varella-
Garcia, M.; Kim, W.-H.; Lynch, T. J.; Fidias, P.; Stubbs, H.; Engelman,
J. A.; Sequist, L. V.; Tan, W.; Gandhi, L.; Mino-Kenudson, M.; Wei,
G. C.; Shreeve, M.; Ratain, M. J.; Settleman, J.; Christensen, J. G.; Haber,
D. A.; Wilner, K.; Salgia, R.i; Shapiro, G. I.; Clark, J. W.; Iafrate, A. J.
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
New Engl. J. Med. 2010, 363, 1693–1703.
(25) Li, R.; Xue, L.; Zhu, T.; Jiang, Q.; Cui, X.; Yan, Z.; McGee, D.;
Wang, J.; Gantla, V. R.; Pickens, J. C.; McGrath, D.; Chucholowski, A.;
Morris, S. W.; Webb, T. R. Design and Synthesis of 5-Aryl-pyridone-
carboxamides as Inhibitors of Anaplastic Lymphoma Kinase. J. Med.
Chem. 2006, 49 (3), 1006–1015.
(26) Sabbatini, P.; Korenchuk, S.; Rowand, J. L.; Groy, A.; Liu, Q.;
Leperi, D.; Atkins, C.; Dumble, M.; Yang, J.; Anderson, K.; Kruger, R. G.;
Gontarek, R. R.; Maksimchuk, K. R.; Suravajjala, S.; Lapierre, R.R.;
Shotwell, J. B.; Wilson, J. W.; Chamberlain, S. D.; Rabindran, S. K.;
Kumar, R. GSK1838705A inhibits the insulin-like growth factor-1
receptor and anaplastic lymphoma kinase and shows antitumor activity
in experimental models of human cancers. Mol. Cancer Ther. 2009, 8
(10), 2811–2820.
(27) Bossi, R. T.; Saccardo, M. B.; Ardini, E.; Menichincheri, M.;
Rusconi, L.; Magnaghi, P.; Orsini, P.; Avanzi, N.; Lombardi Borgia, A.;
Nesi, M.; Bandiera, T.; Fogliatto, G.; Bertrand, J. A. Crystal Structures of
Anaplastic Lymphoma Kinase in Complex with ATP-Competitive
Inhibitors. Biochemistry 2010, 49 (32), 6813–6825.
(28) Deng, X.; Wang, J.; Zhang, J.; Sim, T.; Kim, N. D.; Sasaki, T.;
Luther, W., II; George, R. E.; Janne, P. A.; Gray, N. S. Discovery of 3,5-
Diamino-1,2,4-triazole Ureas as Potent Anaplastic Lymphoma Kinase
Inhibitors. ACS Med. Chem. Lett. 2011, 2, 379–384.
with demonstrated antitumor efficacy in ALK dependent lymphoma and
non small cell lung cancer models. Proc. Am. Assoc. Cancer Res. April,
2009, Abstract 3737.
(32) Milkiewicz, K. L.; Weinberg, L. R.; Albom, M. S.; Angeles, T. S.;
Cheng, M.; Ghose, A. K.; Roemmele, R. C.; Theroff, J. P.; Underiner,
T. L.; Zificsak, C. A.; Dorsey, B. D. Synthesis and structureꢀactivity
relationships of 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and
selective inhibitors of the anaplastic lymphoma kinase. Bioorg. Med.
Chem. 2010, 18, 4351–4362.
(33) Ott, G. R.; Tripathy, R.; Cheng, M.; McHugh, R.; Anzalone, A. V.;
Underiner, T. L.; Curry, M. A.; Quail, M. R.; Lu, L.; Wan, W.; Angeles,
T. S.; Albom, M. S.; Aimone, L. D.; Ator, M. A.; Ruggeri, B. A.; Dorsey,
B. D. Discovery of a Potent Inhibitor of Anaplastic Lymphoma Kinase with
in Vivo Antitumor Activity. ACS Med. Chem. Lett. 2010, 1, 493–498.
(34) Mesaros, E. F.; Burke, J. P.; Parrish, J. D.; Dugan, B. J.;
Anzalone, A. V.; Angeles, T. S.; Albom, M. S.; Aimone, L. D.; Quail,
M. R.; Wan, W.; Lu, L.; Huang, Z.; Ator, M. A.; Ruggeri, B. A.; Cheng,
M.; Ott, G. R.; Dorsey, B. D. Novel 2,3,4,5-tetrahydro-benzo[d]azepine
derivatives of 2,4-diaminopyrimidine, selective and orally bioavailable
ALK inhibitors with antitumor efficacy in ALCL mouse models. Bioorg.
Med. Chem. Lett. 2011, 21, 463–466.
(35) Constraints to form other 6,5-heterocycles have been reported
in the kinase literature, see:(a) Choi, H.-S.; Wang, Z.; Richmond, W.;
He, X.; Yang, K.; Jiang, T.; Sim, T.; Karanewsky, D.; Gu, X.-J.; Zhou, V.;
Liu, Y.; Ohmori, O.; Caldwell, J.; Gray, N.; He, Y. Design and synthesis
of 7H-pyrrolo[2,3-d]pyrimidines as focal adhesion kinase inhibitors.
Part 1, Bioorg. Med. Chem. Lett. 2006, 16, 2173ꢀ2176. (b) Lum, C.; Kahl,
J.; Kessler, L.; Kucharski, J.; Lundstrom, J.; Miller, S.; Nakanishi, H.; Pei,
Y.; Pryor, K.; Roberts, E.; Sebo, L.; Sullivan, R.; Urban, J.; Wang, Z. 2,5-
Diaminopyrimidines and 3,5-disubstituted azapurines as inhibitors of
glycogen synthase kinase-3 (GSK-3). Bioorg. Med. Chem. Lett. 2008,
18, 3578–3581.
(36) Lu, L.; Ghose, A. K.; Quail, M. R.; Albom, M. S.; Durkin, J. T.;
Holskin, B. P.; Angeles, T. S.; Meyer, S. L.; Ruggeri, B. A.; Cheng, M.
ALK Mutants in the Kinase Domain Exhibit Altered Kinase Activity and
Differential Sensitivity to Small Molecule ALK Inhibitors. Biochemistry
2009, 48, 3600–3609.
(37) Choi, Y. L.; Soda, M.; Yamashita, Y.; Ueno, T.; Takashima, J.;
Nakajima, T.; Yatabe, Y.; Takeuchi, K.; Hamada, T.; Haruta, H.;
Ishikawa, Y.; Kimura, H.; Mitsudomi, T.; Tanio, Y.; Mano, H. EML4-
ALK mutations in lung cancer that confer resistance to ALK inhibitors.
New Engl. J. Med. 2010, 363 (18), 1734–1739.
(38) Lee, C. C.; Jia, Y.; Li, N.; Sun, X.; Ng, K.; Ambing, E.; Gao,
M.-Y.; Hua, S.; Chen, C.; Kim, S.; Michellys, P.-Y.; Lesley, S. A.; Harris,
J.; Spraggon, G. Crystal Structure of the Anaplastic Lymphoma Kinase
Catalytic Domain. Biochem. J. 2010, 430, 425–437see also ref 27.
(39) Hayashi, M.; Araki, A.; Maeba, I. C-Nucleosides. 17. A synthesis
of 2-substituted 7-(β-D-ribofuranosyl)pyrrolo[2,1-f]-1,2,4-triazines. A
new type of “purine like” C-nucleoside. Heterocycles 1992, 34, 569–574.
(40) Patil, S. A.; Otter, B. A.; Klein, R. S. 4-Aza-7,9-dideazaadeno-
sine, a new cytotoxic synthetic C-nucleoside analog of adenosine.
Tetrahedron Lett. 1994, 35, 5339–5342.
(41) Hunt, J. T.; Mitt, T.; Borzilleri, R.; Gullo-Brown, J.; Fargnoli, J.;
Fink, B.; Han, W.-C.; Mortillo, S.; Vite, G.; Wautlet, B.; Wong, T.;
Zheng, X.; Bhide, R. Discovery of the pyrrolo[2,1-f][1,2,4]triazine
nucleus as a new kinase inhibitor template. J. Med. Chem. 2004, 47,
4054–4059.
(29) Sakamoto, H.; Tsukaguchi, T.; Hiroshima, S.; Kodama, T.;
Kobayashi, T.; Fukami, T. A.; Oikawa, N.; Tsukuda, T.; Ishii, N.; Aoki, Y.
CH5424802, a Selective ALK Inhibitor Capable of Blocking the
Resistant Gatekeeper Mutant. Cancer Cell 2011, 19 (5), 679–690.
(30) For recent reviews see ref 5 andLi, R.; Morris, S. W. Develop-
ment of anaplastic lymphoma kinase (ALK) small-molecule inhibitors
for cancer therapy. Med. Res. Rev. 2008, 28 (3), 372–412.
(31) Recently, preclinical evaluation of novel small-molecule ALK
inhibitors has been reported, although no structures were disclosed, see:
(a) Katayama, R.; Khan, T. M.; Benes, C.; Lifshits, E.; Ebi, H.; Rivera,
V. M.; Shakespeare, W. C.; Iafrate, A. J.; Engelman, J. A.; Shaw, A. T.
Therapeutic strategies to overcome crizotinib resistance in non-small
cell lung cancers harboring the fusion oncogene EML4-ALK. Proc. Natl.
Acad. Sci. U.S.A. 2011, 108 (18), 7535–7540.(b) Ardini, E.; Menichinch-
eri, M.; De Ponti, C.; Amboldi, N.; Ballinari, D.; Saccardo, M. B.; Croci,
V.; Stellari, F.; Texido, G.; Orsini, P.; Perrone, E.; Bandiera, T.; Borgia,
A. L.; Lansen, J.; Isacchi, A.; Colotta, F. Pesenti, E.; Magnaghi, P.;
Galvani, A. A highly potent, selective and orally available ALK inhibitor
(42) Bhide, R. S.; Cai, Z.-W.; Zhang, Y.-Z.; Qian, L.; Wei, D.;
Barbosa, S.; Lombardo, L. J.; Borzilleri, R. M.; Zheng, X.; Wu, L. I.;
Barrish, J. C.; Kim, S.-H.; Leavitt, K.; Mathur, A.; Leith, L.; Chao, S.;
Wautlet, B.; Mortillo, S.; Jayaseelan, R., Sr.; Kukral, D.; Hunt, J.; Kamath,
A.; Fura, A.; Vyas, V.; Marathe, P.; D’Arienzo, C.; Derbin, G.; Fargnoli, J.
Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-
indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propanol
(BMS-540215), an in vivo active potent VEGFR-2 inhibitor. J. Med.
Chem. 2006, 49, 2143–2146.
(43) Schroeder, G. M.; Chen, X.-T.; Williams, D. K.; Nirschl, D.; Cai,
Z.-W.; Wei, D.; Tokarski, J. S.; An, Y.; Sack, J.; Chen, Z.; Huynh, T.;
6340
dx.doi.org/10.1021/jm200758k |J. Med. Chem. 2011, 54, 6328–6341